Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression

Whole exome sequencing was performed in a patient with myelodysplastic syndrome before and after progression to acute myeloid leukaemia. Mutations in several genes, including SETBP1, were identified following leukaemic transformation. Screening of 328 patients with myeloid disorders revealed SETBP1 mutations in 14 patients (4·3%), 7 of whom had −7/del(7q) and 3 had i(17)(q10), cytogenetic markers associated with shortened overall survival and increased risk of leukaemic evolution. SETBP1 mutations were frequently acquired at the time of leukaemic evolution, coinciding with increase of leukaemic blasts. These data suggest that SETBP1 mutations may play a role in MDS and chronic myelomonocytic leukaemia disease progression.

[1]  M. Heuser,et al.  SETBP1 mutation analysis in 944 patients with MDS and AML , 2013, Leukemia.

[2]  C Haferlach,et al.  SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations , 2013, Leukemia.

[3]  D. Birnbaum,et al.  SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias , 2013, Leukemia.

[4]  Roberta Spinelli,et al.  Recurrent SETBP1 mutations in atypical chronic myeloid leukemia , 2012, Nature Genetics.

[5]  S. Miyano,et al.  Somatic Mutations in Schinzel-Giedion Syndrome Gene SETBP1 Determine Progression in Myeloid Malignancies , 2012 .

[6]  F. Prósper,et al.  Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics , 2012, PloS one.

[7]  M. Odero,et al.  Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia , 2012, Haematologica.

[8]  C. Steidl,et al.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  L. Pasqualucci,et al.  Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. , 2011, Blood.

[10]  S. Sugano,et al.  Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.

[11]  M. Odero,et al.  SETBP1 overexpression is a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid leukemia. , 2010, Blood.

[12]  Ioannis Panagopoulos,et al.  Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12) , 2007, British journal of haematology.

[13]  Y. Lu,et al.  Gain of 1q25–32, 12q23–24.3, and 17q12–22 facilitates tumorigenesis and progression of human squamous cell lung cancer , 2006, The Journal of pathology.

[14]  V. Lazarevic,et al.  Abnormalities of chromosome 17 in myelodysplastic syndromes: Incidence and biological significance , 2004 .

[15]  V. Lazarevic,et al.  [Chromosome 17 abnormalities in patients with primary myelodysplastic syndrome: incidence and biologic significance]. , 2004, Srpski arhiv za celokupno lekarstvo.

[16]  M. Wadleigh,et al.  Myelodysplasia , 2001, Bone Marrow Transplantation.